Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.
Wang J, Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Yu H, Zhao Y, Chen W, Luo Y, Wang X, Nan K, Jin F, Dong J, Li B, Liu Z, Han B, Li K.
Wang J, et al. Among authors: wang x, wang z, wang q.
Cancer Biol Med. 2018 Nov;15(4):443-451. doi: 10.20892/j.issn.2095-3941.2018.0158.
Cancer Biol Med. 2018.
PMID: 30766754
Free PMC article.